Medical Education Events Research Articles

Mayo International Spine Symposium 2010

This annual 5-day Continued Medical Education event featured the latest in new treatment strategies and techniques for orthopedists, neurosurgeons, physiatrists, primary care providers and other professionals involved in treating patients with spinal disorders. This year’s program content focused on: minimally invasive surgery, motion-preservation surgery, nonoperative spine care, value (quality/cost) and maintenance of certification self-assessment examination.

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary - Meetings

Continuing Medical Education Event Diary - Meetings

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Meetings

Clinical OtolaryngologyVolume 35, Issue 1 p. 79-79 Continuing Medical Education Event Diary – Meetings First published: 22 February 2010 https://doi.org/10.1111/j.1749-4486.2009.02079_1.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume35, Issue1February 2010Pages 79-79 RelatedInformation

Continuing Medical Education Event Diary – Meetings

Continuing Medical Education Event Diary – Meetings

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Courses

Work Productivity Improvements in Adalimumab-treated Patients with Moderate to Severe Ileocolonic Crohnʼs Disease: The EXTEND Trial

Purpose: The ability of anti-tumor necrosis factor (anti-TNF) therapy to restore work capacity in Crohn's disease (CD) has not been fully defined. We assessed the impact of adalimumab on work productivity in EXTEND, a 52-week, placebo-controlled study of the effect of adalimumab on mucosal healing in patients with moderate to severe ileocolonic CD. Methods: All patients received open-label adalimumab 160-/80-mg induction therapy at Weeks 0/2 and were randomized to adalimumab 40 mg every other week (eow) or placebo at Week 4. From Week 8, patients with flares or nonresponse could receive open-label adalimumab. The Work Productivity and Activity Impairment Questionnaire (WPAI) is a validated, self-administered tool that assesses impact of disease on productivity. The WPAI measures CD-related impairment in work productivity and daily activity via 4 component scores: absenteeism (CD-related absence from work), presenteeism (CD-related impairment of productivity during work), total work productivity impairment (TWPI; absenteeism and presenteeism combined), and total activity impairment (TAI; CD-related daily activity impairment). Differences in productivity between the continuous adalimumab group and the inductiononly placebo group were analyzed for the double-blind period via last-observation-carried-forward (LOCF) imputation. Only evaluations after Week 4 of double-blind treatment were carried forward; data after first open-label dose were excluded. Results: Of 129 patients randomized in EXTEND, 63% were women, 92% were white, mean age was 37 years, mean Crohn's Disease Activity Index was 320, mean CD duration was 10 years, and 61% were anti-TNF experienced. Concomitant steroids were used by 26% and immunosuppressants, by 41%. At Week 4, following treatment with the loading dose, all components of WPAI improved significantly (absenteeism: -18; presenteeism: -25; TWPI: -28; TAI: -25). At Week 52, the continuous adalimumab group experienced significant improvements in missed work time, daily activity impairment, and overall work impairment vs. the induction-only placebo group (Table). Conclusion: Adalimumab maintenance therapy was associated with significant and sustained improvements in work productivity and daily activity compared with the induction-only placebo therapy in patients with moderate to severe ileocolonic CD. Disclosure: Dr Binion - Speaker's bureau: Abbott Laboratories, Centocor, Elan Pharmaceuticals, Procter & Gamble Pharmaceuticals, Prometheus, Salix, Shire, and UCB Grants: the National Institute of Health, Centocor, Elan Biogen and Procter & Gamble Pharmaceuticals. Dr Rutgeerts - Served as study investigator and consultant for Abbott Laboratories and has participated in continuing medical education events supported by unrestricted educational grants from Abbott (research support, consultant fees, speaker's fees) Dr Chen - Employee - Abbott Dr Chao - Employee, stocks - Abbott Dr Mulani - Employee, stocks - Abbott. This research was funded by Abbott Laboratories, Abbott Park, IL.Table: WPAI change from baseline to week 52: LOCF

Adalimumab Downregulates Markers of Inflammation in Patients with Moderate to Severe Ileocolonic Crohnʼs Disease: The Histologic Substudy of EXTEND

Purpose: Adalimumab is effective for inducing and maintaining remission in Crohn's disease (CD), but its efficacy for mucosal healing on a histologic basis has not been studied. Methods: EXTEND was a placebo-controlled study of patients with moderate to severe CD (Crohn's Disease Activity Index 220-450). All patients received open-label (OL) adalimumab 160-/80-mg induction therapy at Weeks 0/2 and were randomized at Week 4 to maintenance therapy with adalimumab 40 mg every other week (eow) or placebo (induction-only placebo [IO]) through Week 52. From Week 8, patients with flares or nonresponse could receive OL adalimumab 40 mg eow (weekly if flares/nonresponse continued). Patients underwent colonoscopies at baseline, Week 12 (or unscheduled visits Weeks 8-12 prior to switch to OL therapy), time of switch to OL adalimumab (if after Week 12), and Week 52 (or early termination). Week-12 data include blinded therapy only; Week-52 data include original randomized groups irrespective of dosing change. Histology substudy endpoints included ileal and colonic Global Histologic Disease Activity Scores (IGHAS, CGHAS) at baseline, Week 12, and Week 52. Immunohistochemistry endpoints included colonic expression of tumor necrosis factor (TNF), myeloperoxidase (MPO), and human leukocyte antigen DR (HLA-DR) at baseline and Week 12. The pathologist was blinded to clinical information. Results: 135 patients were enrolled, and 129 were randomized. At baseline, the continuous adalimumab and IO groups were comparable in mean and maximum IGHAS and CGHAS scores and in colonic expression of TNF, MPO, and HLA-DR. IGHAS and CGHAS decreased in both groups and remained low between Weeks 12 and 52 (table). Mean IGHAS and CGHAS changes from baseline were statistically significant within treatments (p<0.001) but not between continuous adalimumab vs. IO. Colonic expression of TNF, MPO, and HLA-DR at Week 12 was significantly less for the continuous adalimumab group vs. the IO group (p≤0.05 for all comparisons from analysis of variance model with treatment as factor). Conclusion: By Week 12, continuous adalimumab therapy induced histologic mucosal healing and downregulation of TNF and markers of inflammation that persisted through Week 52. Disclosure: Dr Rutgeerts: Served as study investigator and consultant for Abbott Laboratories and has participated in continuing medical education events supported by unrestricted educational grants from Abbott (research support, consultant fees, speaker's fees) Dr Camez - Employee, stocks: Abbott Dr Lazar - Employee, stocks: Abbott Dr Lomax - Employee: Abbott. This research was supported by an industry grant from Abbott Laboratories.Table: Histology substudy results from the EXTEND trial IGHAS/CGHAS (mean values)

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Meetings

Continuing Medical Education Event Diary – Meetings

Five Decades of Indian Nephrology: A Personal Journey

Impressive accomplishments have been made in Indian nephrology during the last 5 decades. The first renal biopsy performed in 1956 ushered in a new era of modern nephrology practice in India and led to the recognition of nephrology as a distinct specialty. The first hemodialysis facility was established in 1961; presently, there are 950 nephrologists, 850 hospitals equipped with dialysis facilities, and 170 institutions recognized for kidney transplantation, with approximately 3,500 transplantations performed every year. The majority of dialysis units are small minimal-care facilities with fewer than 5 dialysis stations, and more than 85% are in the private sector. Government hospitals provide free treatment to poor patients with chronic kidney disease; however, inadequate funding and lack of health insurance schemes pose serious hurdles in providing renal replacement therapy. In contrast, private/corporate hospitals located in big cities have large units with state-of-the-art dialysis and transplantation facilities, similar to advanced centers of the world, but are accessible to only upper-income groups. Of the estimated 175,000 new patients who develop end-stage renal disease annually, less than 10% are able to gain access to renal replacement therapy. Research in the field of renal diseases has evolved slowly and is focused primarily on tropical conditions. The availability of structured nephrology training programs coupled with excellent diagnostic and therapeutic facilities in some academic institutions and tertiary-care private/corporate hospitals have diminished the need for foreign travel by students, patients, and consultants to a considerable extent. The expansion of therapeutic facilities in India is hampered by only economic constraints, not lack of expertise.

Continuing Medical Education Event Diary – Courses

Clinical OtolaryngologyVolume 34, Issue 4 p. 419-420 Continuing Medical Education Event Diary – Courses First published: 23 July 2009 https://doi.org/10.1111/j.1749-4486.2009.01993_2.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume34, Issue4August 2009Pages 419-420 RelatedInformation

Continuing Medical Education Event Diary – Meetings

Clinical OtolaryngologyVolume 34, Issue 4 p. 418-418 Continuing Medical Education Event Diary – Meetings First published: 23 July 2009 https://doi.org/10.1111/j.1749-4486.2009.01993_1.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume34, Issue4August 2009Pages 418-418 RelatedInformation

Continuing Medical Education Event Diary – Meetings

Clinical OtolaryngologyVolume 34, Issue 3 p. 297-297 Continuing Medical Education Event Diary – Meetings First published: 28 May 2009 https://doi.org/10.1111/j.1749-4486.2008.01943_1.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume34, Issue3June 2009Pages 297-297 RelatedInformation

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Courses

Continuing Medical Education Event Diary – Meetings

Clinical OtolaryngologyVolume 34, Issue 2 p. 185-185 Continuing Medical Education Event Diary – Meetings First published: 08 April 2009 https://doi.org/10.1111/j.1749-4486.2009.01912_1.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume34, Issue2April 2009Pages 185-185 RelatedInformation

Continuing Medical Education Event Diary – Courses

Clinical OtolaryngologyVolume 34, Issue 2 p. 186-187 Continuing Medical Education Event Diary – Courses First published: 08 April 2009 https://doi.org/10.1111/j.1749-4486.2008.01912_2.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume34, Issue2April 2009Pages 186-187 RelatedInformation

Continuing Medical Education Event Diary - Meetings

Clinical OtolaryngologyVolume 34, Issue 1 p. 93-93 Continuing Medical Education Event Diary – Meetings First published: 19 February 2009 https://doi.org/10.1111/j.1749-4486.2008.01883_1.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume34, Issue1February 2009Pages 93-93 RelatedInformation

Continuing Medical Education Event Diary - Courses

Clinical OtolaryngologyVolume 34, Issue 1 p. 94-96 Continuing Medical Education Event Diary – Courses First published: 19 February 2009 https://doi.org/10.1111/j.1749-4486.2008.01883_2.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Volume34, Issue1February 2009Pages 94-96 RelatedInformation